A review of Ciclesonide in COVID-19. Still a long way to go

Adv Respir Med. 2021;89(1):79-81. doi: 10.5603/ARM.a2020.0173. Epub 2021 Jan 20.

Abstract

As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.

Keywords: COVID 19; ciclesonide; repurposed drug.

MeSH terms

  • Administration, Inhalation
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Drug Repositioning*
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Pregnenediones / therapeutic use*
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Pregnenediones
  • ciclesonide